Revolution Medicines (RVMD)
(Delayed Data from NSDQ)
$38.39 USD
+1.21 (3.25%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $38.37 -0.02 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RVMD 38.39 +1.21(3.25%)
Will RVMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RVMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RVMD
Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade
Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?
RVMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?
Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround
Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for RVMD
What To Expect From Revolution Medicines Inc (RVMD) Q2 2025 Earnings
Revolution Medicines Inc (RVMD) Announces Upcoming Q2 2025 Financial Results Release | RVMD ...
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on ...
Revolution Medicines Inc (RVMD) Unveils Breakthrough in Targeted Cancer Therapy | RVMD stock news
Revolution Medicines (RVMD) Publishes Breakthrough on Zoldonrasib Targeting RAS G12D | RVMD ...